Boceprevir as a viable HCV treatment: Making dosage more manageable

被引：0
|
作者：
Santori, Clarissa [1 ]
Fritsche, Melanie [1 ]
Andes, Amy [1 ]
Kresse, Isaac [1 ]
Jones, Graham [1 ]
机构：
[1] Northeastern Univ, Chem, Boston, MA 02115 USA
来源：
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY | 2016年 / 251卷
关键词：
D O I：
暂无
中图分类号：
O6 [化学];
学科分类号：
0703 ;
摘要：
135
引用
收藏
页数：1
相关论文
共 50 条
  • [31] ANALYSIS OF SUSTAINED VIRAL RESPONSE AND BOCEPREVIR RESISTANCE FOLLOWING COMBINATION TREATMENT WITH BOCEPREVIR PLUS PEGINTERFERON ALFA-2A/RIBAVIRIN IN HCV GENOTYPE 1 PRIOR RELAPSERS AND NON-RESPONDERS
    Howe, John A.
    Ogert, Robert A.
    Barnard, Richard J.
    Hazuda, Dada
    Pedicone, Lisa
    Brass, Clifford A.
    Albrecht, Janice K.
    Flamm, Steven L.
    HEPATOLOGY, 2011, 54 : 443A - 443A
  • [32] Boceprevir for chronic HCV genotype 1 infection in patients with prior treatment failure to peginterferon/ribavirin, including prior null response
    Vierling, John M.
    Davis, Mitchell
    Flamm, Steven
    Gordon, Stuart C.
    Lawitz, Eric
    Yoshida, Eric M.
    Galati, Joseph
    Luketic, Velimir
    McCone, Jonathan
    Jacobson, Ira
    Marcellin, Patrick
    Muir, Andrew J.
    Poordad, Fred
    Pedicone, Lisa D.
    Albrecht, Janice
    Brass, Clifford
    Howe, Anita Y. M.
    Colvard, Lynn Y.
    Helmond, Frans A.
    Deng, Weiping
    Treitel, Michelle
    Wahl, Janice
    Bronowicki, Jean-Pierre
    JOURNAL OF HEPATOLOGY, 2014, 60 (04) : 748 - 756
  • [33] Patient Decision-Making: The Informational Needs of Patients Making Decisions about HCV Treatment
    Evon, Donna M.
    Golin, Carol E.
    Jones, Rachel E.
    Stoica, Teodora
    Willis, Sarah
    Fried, Michael W.
    HEPATOLOGY, 2015, 62 : 758A - 758A
  • [34] Options for making your dental treatment more comfortable
    Mark, Anita M.
    JOURNAL OF THE AMERICAN DENTAL ASSOCIATION, 2022, 153 (02): : 192 - 192
  • [35] Comment about making outcome of treatment more predictable
    Becker, A
    AMERICAN JOURNAL OF ORTHODONTICS AND DENTOFACIAL ORTHOPEDICS, 1997, 112 (04) : A17 - A18
  • [36] Pharmacogenetics: Making Cancer Treatment Safer and More Effective
    不详
    ONCOLOGY NURSING FORUM, 2010, 37 (04) : 512 - 512
  • [37] Boceprevir and telaprevir-based regimens for the treatment of hepatitis C virus in a real world HIV/HCV co-infected cohort
    Beste, Lauren A.
    Green, Pamela
    Ioannou, George N.
    HEPATOLOGY, 2014, 60 : 932A - 933A
  • [38] The statistical treatment of toxicological data relating to more than one dosage factor
    Finney, DJ
    ANNALS OF APPLIED BIOLOGY, 1943, 30 (01) : 71 - 79
  • [39] FUTILITY TESTING AT TREATMENT WEEK 8 IN PATIENTS WITH HEPATITIS C VIRUS (HCV) GENOTYPE 1 INFECTION RECEIVING BOCEPREVIR: A POST HOC ANALYSIS
    Jacobson, I. M.
    Silva, M.
    Bruno, S.
    Calleja, J. -L.
    Bacon, B.
    Esteban, R.
    Poordad, F.
    Bronowicki, J. -P.
    Sulkowski, M. S.
    Vierling, J. M.
    Flamm, S.
    Colvard, L.
    Thompson, S.
    Koury, K.
    Helmond, F. A.
    Alves, K.
    Wahl, J.
    JOURNAL OF HEPATOLOGY, 2014, 60 (01) : S457 - S458
  • [40] Virologic Responses and Safety of the current NS3/4A Protease Inhibitors (Telaprevir and Boceprevir) in HCV Treatment-Experienced patients
    Mousa, Omar
    Pham, Ly-Elaine
    Egwim, Chukwuma I.
    Zela, Scott A.
    Ankoma-Sey, Victor
    HEPATOLOGY, 2012, 56 : 1039A - 1040A
12345